Lentiviral and AAV-mediated expression of palivizumab offer protection against Respiratory Syncytial Virus infection
File(s)s41598-021-95150-z.pdf (887.67 KB)
Published version
Author(s)
Type
Journal Article
Abstract
Respiratory syncytial virus (RSV) infection is a common cause of hospitalisation in infants and the elderly. Palivizumab prophylaxis is the only approved treatment modality but is costly and only offered to select vulnerable populations. Here, we investigated gene delivery approaches via recombinant adeno-associated virus (rAAV2/8) and simian immunodeficiency virus (rSIV.F/HN) vectors to achieve sustained in vivo production of palivizumab in a murine model. Delivery of palivizumab-expressing vectors 28 days prior to RSV challenge resulted in complete protection from RSV-induced weight loss. This approach offers prophylaxis against RSV infection, allowing for wider use and reduction in treatment costs in vulnerable populations.
Date Issued
2021-12
Date Acceptance
2021-07-20
Citation
Scientific Reports, 2021, 11 (1), pp.1-12
ISSN
2045-2322
Publisher
Nature Publishing Group
Start Page
1
End Page
12
Journal / Book Title
Scientific Reports
Volume
11
Issue
1
Copyright Statement
© The Author(s) 2021. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
License URL
Sponsor
Wellcome Trust
Identifier
https://www.nature.com/articles/s41598-021-95150-z
Grant Number
109058/Z/15/Z
Publication Status
Published
Article Number
15694
Date Publish Online
2021-08-03